MedTrace Logo

Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma

NCT01095094 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2013-06-10

Study results available
· View outcomes & findings →

Summary

RATIONALE: Ritonavir and lopinavir may stop the growth of gliomas by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well giving ritonavir together with lopinavir works in treating patients with progressive or recurrent high-grade glioma.

Conditions

  • Brain Tumor
  • Anaplastic Astrocytoma
  • Anaplastic Ependymoma
  • Anaplastic Oligodendroglioma
  • Brain Stem Glioma
  • Giant Cell Glioblastoma
  • Glioblastoma
  • Gliosarcoma
  • Mixed Glioma

Interventions

DRUG

ritonavir

Given orally

DRUG

lopinavir

Given orally

Sponsors & Collaborators

  • Case Comprehensive Cancer Center

    lead OTHER

Principal Investigators

  • David Peereboom, MD · Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2010-06-30
Completion
2011-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01095094 on ClinicalTrials.gov